modelAmisulpride_Liu2023_reference

Extends from Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral.

Information

name:amisulpride
ATC code:N05AL05
model:one compartment, oral dosing (PK_1C_enteral)
source:Liu W et al. 2023
population:adult Chinese patients with schizophrenia
measured compound:amisulpride
review:curated candidate
record page:pharmacolibrary-docs

Parameters as reported in the paper

parametervalueunitmeaning
CL/F32.6L/hCL/F
V/F391LV/F
ka0.9h -1kabs

About amisulpride

Amisulpride is an antipsychotic medicine used to treat schizophrenia. It is an approved drug and remains in clinical use, mainly in Europe.

Summary written by glm-5.3-flash from Wikidata Q418785 and the WHO ATC classification; not checked by a person.

Identity, molar mass and metabolites: Amisulpride.

References

  1. Liu W et al. (2023). A pharmacokinetic analysis of amisulpride in adult Chinese patients with schizophrenia: Impact of creatinine clearance. International journal of clinical pharmacology and therapeutics. DOI:10.5414/CP204334 PUBMED:36871243

Parameters

TypeNameDefaultDescription
RealCl_ref9.055555555555556e-06Cl [m3/s]
RealVd_ref0.391Vd [m3]
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.0009Volume of distribution per kg (default 0.9 L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)1bioavailability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)2.7777777777777776e-7clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1e-4administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)
Info › Therapeutic range (metadata, not used in equations)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008maximal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Info › Substance metadata
Modelica.Units.SI.MolarMassMM (from PK_1C)0molar mass [kg/mol]; 0 = not supplied (molar concentrations are then 0)
Info › Substance metadata (not used in equations)
Pharmacolibrary.Types.DoseLD50 (from PK_1C)0median lethal dose [mg/kg]; 0 = unknown

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)central-compartment elimination half-life = ln(2)*Vd/Cl (1-compartment approximation; NOT the terminal half-life of 2-/3-compartment models)

Revisions

  • 11/2026 generated by pharmacolibrary-dev export.pharmacolibrary_models from Liu_2023: parameters extracted from the paper by the pharmacolibrary-dev pipeline, model built by its engineer, reviewed: curated candidate